Carcinoid syndrome surgery

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Carcinoid syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Carcinoid Syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Carcinoid syndrome surgery On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Carcinoid syndrome surgery All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Carcinoid syndrome surgery
CDC on Carcinoid syndrome surgery
Carcinoid syndrome surgery in the news
Blogs on Carcinoid syndrome surgery
Directions to Hospitals Treating Carcinoid syndrome
Risk calculators and risk factors for Carcinoid syndrome surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

For qualifying candidates, surgical resection of tumor and chemotherapy (5-FU and doxorubicin) can improve outcomes.

Surgery

Surgery, if feasible, is the only curative therapy. If the tumour has metastasized (most commonly, to the liver), the tumour may be ineligible for surgery (unresectable), though there are many promising treatment modalities, such as radiolabeled octreotide, that are very effective in arresting the growth of the tumours and prolonging survival in patients with liver metastases.

References

Template:WikiDoc Sources